본문바로가기
Q
U
I
C
K

PR

SK bioscience company news updates

Media Zoom

SK bioscience-GSK’s Covid-19 vaccine meets Phase III trial’s coprimary goals

2022.05.02



SK bioscience and GlaxoSmithKline (GSK) have reported that their recombinant, protein-based, Covid-19 vaccine candidate, SKYCovione (GBP510/GSK adjuvant) met the coprimary goals in the Phase III clinical trial.

A self-assembled nanoparticle vaccine candidate, SKYCovione acts on the receptor-binding domain of the Spike protein of the SARS-CoV-2 virus.